Among them, tagraxofusp (SL-401), a CD123-targeting fusion protein conjugated to diphtheria toxin, has been FDA-approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is being evaluated in AML [84]. Here, IL3RA is linked to CD4+/CD56+ hematodermic neoplasm.